Summarized by Masters of Longevity from Longevity Technology.
A brief look at a biotech’s plan to use an AI regulatory-drafting platform to accelerate preparing a major drug filing, and what that approach could mean for filing workflows.
Key Takeaways
- Annovis Bio is using an AI regulatory-drafting platform to prepare much of its buntanetap NDA before top-line Phase 3 data arrive.
- Buntanetap targets multiple neurotoxic proteins via an RNA-targeting mechanism, aiming to treat both Alzheimer’s and Parkinson’s disease.
- Annovis retains final responsibility for all submission content, with AI limited to drafting, organizing, and document management.
